Cargando…

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies

The myeloproliferative neoplasms (MPNs) are a group of clonal hematological malignancies characterized by a hypercellular bone marrow and a tendency to develop thrombotic complications and to evolve to myelofibrosis and acute leukemia. Unlike chronic myelogenous leukemia, where a single disease-init...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mascarenhas, John, Roper, Nitin, Chaurasia, Pratima, Hoffman, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365400/ https://www.ncbi.nlm.nih.gov/pubmed/22704337 http://dx.doi.org/10.1007/s13148-011-0050-6

Ejemplares similares

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

AKT is a therapeutic target in myeloproliferative neoplasms
por: Khan, Irum, et al.
Publicado: (2013)

Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
por: Brkic, Sime, et al.
Publicado: (2020)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
por: Sharma, Vasundhara, et al.
Publicado: (2020)

Prognostication in myeloproliferative neoplasms, including mutational abnormalities
por: Hong, Junshik
Publicado: (2023)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

The possible role of mutated endothelial cells in myeloproliferative neoplasms
por: Farina, Mirko, et al.
Publicado: (2021)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
por: Tripodi, Joseph, et al.
Publicado: (2010)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
por: Ajufo, Helen O., et al.
Publicado: (2023)

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
por: Orlova, Anna, et al.
Publicado: (2017)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
por: Wang, Xiaoli, et al.
Publicado: (2022)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells
por: Saleiro, Diana, et al.
Publicado: (2023)

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
por: Petiti, Jessica, et al.
Publicado: (2020)

Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms
por: Shen, Zhu, et al.
Publicado: (2021)

Targeting Rho Associated Kinases in Leukemia and Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
por: Purwar, Shubhrat, et al.
Publicado: (2023)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gl8brmhfi6ft7sha38j1eobaub